Approvals in 2022: overall survival, dose optimization, new approvals and beyond
Crossref DOI link: https://doi.org/10.1038/s41571-023-00741-6
Published Online: 2023-02-23
Published Print: 2023-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Telaraja, Deepti
Gormley, Nicole
Pazdur, Richard http://orcid.org/0000-0002-4771-9923
Text and Data Mining valid from 2023-02-23
Version of Record valid from 2023-02-23
Article History
First Online: 23 February 2023
Competing interests
: The authors declare no competing interests.